Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis

被引：0
|
作者：
Diana Lacruz-Guzmán
Daniel Torres-Moreno
Francisco Pedrero
Patricia Romero-Cara
Iván García-Tercero
Javier Trujillo-Santos
Pablo Conesa-Zamora
机构：
[1] Santa Lucía General University Hospital (HGUSL),Pharmacy Department
[2] HGUSL,Molecular Pathology and Pharmacogenetics Group FFIS011, Pathology Department
[3] HGUSL,Day Hospital
[4] HUGSL,Gastroenterology Department
[5] HUGSL,Internal Medicine
来源：
European Journal of Clinical Pharmacology | 2013年 / 69卷
关键词：
Tumour necrosis factor; Interleukin-1; Infliximab; Crohn’s disease; Pharmacogenetics; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 438
页数：7
相关论文
共 50 条
  • [1] Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis
    Lacruz-Guzman, Diana
    Torres-Moreno, Daniel
    Pedrero, Francisco
    Romero-Cara, Patricia
    Garcia-Tercero, Ivan
    Trujillo-Santos, Javier
    Conesa-Zamora, Pablo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) : 431 - 438
  • [2] Monocytic TNF production predicts response to infliximab treatment in Crohn's disease but not ulcerative colitis
    Jessen, B.
    Lissner, D.
    Sonnenberg, E.
    Schumann, M.
    Schmidt, F.
    Kuehl, A.
    Siegmund, B.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S355 - S356
  • [3] THE INFLUENCE OF INFLIXIMAB ON POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE
    Ma, J.
    Trencheva, K.
    Sonoda, T.
    Shukla, P.
    Milsom, J.
    Lee, S.
    DISEASES OF THE COLON & RECTUM, 2011, 54 (05) : E105 - E105
  • [4] TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis
    Owczarek, Danuta
    Cibor, Dorota
    Glowacki, Mikolaj K.
    Ciesla, Andrzej
    Mach, Pawel
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2012, 122 (12): : 616 - 623
  • [5] Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis
    Ananthakrishnan, Ashwin N.
    Cagan, Andrew
    Cai, Tianxi
    Gainer, Vivian S.
    Shaw, Stanley Y.
    Savova, Guergana
    Churchill, Susanne
    Karlson, Elizabeth W.
    Kohane, Isaac
    Liao, Katherine P.
    Murphy, Shawn N.
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (04) : 880 - 885
  • [6] Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis
    Ananthakrishnan, Ashwin N.
    Cagan, Andrew
    Cai, Tianxi
    Gainer, Vivian S.
    Shaw, Stanley
    Churchill, Susanne
    Karlson, Elizabeth
    Kohane, Isaac
    Liao, Katherine
    Murphy, Shawn
    GASTROENTEROLOGY, 2016, 150 (04) : S979 - S979
  • [7] Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis
    Behm B.W.
    Bickston S.J.
    Current Treatment Options in Gastroenterology, 2007, 10 (3) : 171 - 177
  • [8] Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
    Taxonera, Carlos
    Olivares, David
    Mendoza, Juan L.
    Diaz-Rubio, Manuel
    Rey, Enrique
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (27) : 9170 - 9177
  • [9] Infliximab reduces Hypercoagulability in Patients with Crohn's Disease and Ulcerative Colitis
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (11): : 1046 - 1046
  • [10] Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
    Carlos Taxonera
    David Olivares
    Juan L Mendoza
    Manuel Díaz-Rubio
    Enrique Rey
    World Journal of Gastroenterology, 2014, 20 (27) : 9170 - 9177
12345